Boston, Mass., – Intellimedix announced today that it is introducing a new exome product for the research market that will incorporate and leverage the exome sequencing service of BGI Tech Solutions Co., LTD, a subsidiary of BGI, the world’s largest genomics organization, along with Intellimedix’s proprietary analysis algorithms. The product, to be called “Enhanced Accelerated Exome”, will offer both Next Generation Sequencing (NGS) and a genome-wide interpretation, and deliver a far more comprehensive analysis with much faster turnaround than current industry norms. Enhanced Accelerated Exome, introduced at the 7th Annual BioPharm America Conference in Boston, will be available from Intellimedix beginning in November of this year.
BGI Tech provides exome sequencing on the Ion Proton platform with 100x coverage and with an extremely fast turnaround time of seven days from sample to results. SNP validation is also provided to further assure the accuracy of the results. Packaged with BGI Tech’s service, Intellimedix will provide fully interpreted, annotated sequencing of the entire exome in an additional three days. This combined ten-day turnaround compares to an industry norm of approximately eight weeks.
According to Intellimedix’s Dr. Jeffrey Skolnick, “We are pleased to work with BGI Tech to provide researchers a new exome product that is dramatically better than anything available on the market today. BGI Tech provides high-quality service, very rapid turnaround and highly capable project management, which makes them the ideal partner for this new product. Our joint effort will redefine customer service in the exome research marketplace, setting a new standard across the genomic sequencing and interpretation industry.”
Intellimedix’s new interpretative software PROGNOSTIX, developed by Dr. Skolnick and his research group at Georgia Tech, is the first algorithm capable of not only covering whole exomes, but also using 3D protein structure to make more precise predictions about a DNA mutation’s possible pathogenicity, or the likelihood of the ability of a mutation to be associated with a disease. Compared to the industry standard 30% exome coverage rate, this novel algorithm offers greater than 80% coverage with a 3x lower rate of false positives.
“We welcome the opportunity to enable Intellimedix’s new product offering by providing our exome sequencing service that delivers 100x coverage in seven days,” stated Yingrui Li, CEO of BGI Tech . “Coupling our exome service with Intellimedix’s proprietary algorithms will provide researchers rapid, in-depth sequencing with enhanced annotation and interpretation.”
About BGI Tech Solutions Co., LTD
BGI Tech, a subsidiary of BGI, the world’s largest genomics organization, provides sequencing and bioinformatics service solutions for global biomedical, agricultural, and environmental customers. Equipped with the industry’s broadest array of cutting-edge technologies, BGI Tech delivers rapid, cost-effective and high-quality results that enable researchers to achieve scientific breakthroughs. BGI Tech has provided premier services to more than 10,000 research institutes and 30,000 scientific partners, resulting in more than 600 publications, including 100 in top-tier journals such as Nature and Science.
For more information visit bgitechsolutions.com.
Intellimedix develops innovative approaches to accelerate the discovery and development of new treatments for known human diseases. The company, headquartered in Atlanta, GA with a research laboratory in Cambridge, MA, is guided by the principle of open innovation. Intellimedix works closely with patients and their doctors, non-profits, and academic institutions in order to promote the free flow of knowledge and information for the benefit of all. Intellimedix has teamed up with world-class experts in the fields of systems biology, computer science, neuroscience and biological engineering.